GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update
April 26 2021 - 9:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a
biotechnology company developing human immunotherapies and vaccines
against infectious diseases and cancer, announces today that it
will report first quarter 2021 financial results on Thursday, May
6, 2021 after the market closes.
Management will host a conference call at 4:30
p.m. ET on Thursday, May 6, 2021 to review financial results and
provide an update on corporate developments. Following
management’s formal remarks, there will be a question and answer
session.
Participants are asked to pre-register for the
call via the following link:
https://dpregister.com/sreg/10155713/e7b7b09fcc
Please note that registered participants will
receive their dial-in number upon registration and will dial
directly into the call without delay. Those without Internet
access or who are unable to pre-register may dial in by calling
1-866-777-2509 (domestic) or 1-412-317-5413 (international).
All callers should dial in approximately 10 minutes prior to the
scheduled start time and ask to be joined into the GeoVax Labs
call.
The conference call will be available through a
live webcast found here:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=8qJmr12T
A webcast replay of the call will be available via
the same link as the live webcast approximately one hour after the
end of the call through August 6, 2021. A telephonic replay
of the call can be accessed by calling 1-877-344-7529 (domestic) or
1-412-317-0088 (international) and using access code 10155713. The
telephonic replay will be available until May 20, 2021.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On
this platform, MVA, a large virus capable of carrying several
vaccine antigens, expresses proteins that assemble into VLP
immunogens in the person receiving the vaccine. The production of
VLPs in the person being vaccinated can mimic virus production in a
natural infection, stimulating both the humoral and cellular arms
of the immune system to recognize, prevent, and control the target
infection. The MVA-VLP derived vaccines can elicit durable immune
responses in the host similar to a live-attenuated virus, while
providing the safety characteristics of a replication-defective
vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia;
human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of
two separate collaborative efforts to apply its innovative gene
therapy approach toward a functional cure for HIV.
Cautionary Note Regarding Forward-Looking
Statements
This release and the related conference call
contain forward-looking statements regarding GeoVax’s business
plans and financial results. The words “believe,” “may,”
“estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“could,” “target,” “potential,” “is likely,” “will,” “expect” and
similar expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events and financial trends that we believe may affect
our financial condition, results of operations, business strategy
and financial needs. Actual results may differ materially from
those included in these statements due to a variety of factors,
including whether: GeoVax can develop and manufacture its vaccines
with the desired characteristics in a timely manner, GeoVax’s
vaccines will be safe for human use, GeoVax’s vaccines will
effectively prevent targeted infections in humans, GeoVax’s
vaccines will receive regulatory approvals necessary to be licensed
and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may
be more effective or easier to use than GeoVax’s products, GeoVax
will be able to enter into favorable manufacturing and distribution
agreements, the impact of the COVID-19 pandemic continues, and
other factors, over which GeoVax has no control.
Further information on our risk factors is
contained in our registration statement on Form S-3 and the
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Sep 2023 to Sep 2024